Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
NYSE MKT:NBY
NovaBay Pharma (NBY) Stock Price & Analysis
570 Followers
NBY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.08 - $1.95
Previous Close$0.08
Volume1.84M
Average Volume (3M)3.28M
Market Cap
$2.94M
Enterprise Value$2.55M
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$2.74M
Price to Earnings (P/E)>-0.1
Beta1.03
Next Earnings
May 09, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding30,098,150
10 Day Avg. Volume1,609,851
30 Day Avg. Volume3,279,509
Standard Deviation0.44
R-Squared0.06
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.90
Price to Sales (P/S)0.18
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit0.32
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$2.60Price Target Upside3170.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NovaBay Pharma News
Ownership Overview
94.02% Insiders
0.12% Mutual Funds
2.37% Other Institutional Investors
3.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $0.08 and its highest was $1.95 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Currently, no data Available
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 22 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Novabay Pharmaceuticals released its earnings results on Mar 26, 2024. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$1.03.
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Undervalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals does not currently pay dividends.
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate is -$0.15.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 36,060,825 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Novabay Pharmaceuticals reported an EPS of -$1.33 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
---
NovaBay Pharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.60 (3170.44% Upside)
$2.60 (3170.44% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 4.3%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.50%
12-Months-Change
Fundamentals
Return on Equity
-139.03%
Trailing 12-Months
Asset Growth
-44.91%
Trailing 12-Months
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
---
NBY Earnings Call
Q4 2024
0:00 / 0:00
---
NBY Stock 12 Months Forecast
Average Price Target
$2.60
▲(3170.44% Upside)
Technical Analysis
Best Analysts Covering NBY
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-69.84%
reiterated a buy rating 5 days ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -69.84% per trade.
---